Azurocidin Recombinant Protein Cat. No.: 91-386

Availability: In stock

$0.00

No Image

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Human
SOURCE SPECIES:Human Cells
SEQUENCE:Ile27-Pro250
FUSION TAG:C-6 His tag
TESTED APPLICATIONS:
APPLICATIONS:This recombinant protein can be used for biological assays. For research use only.
psi-iconProperties
PURITY:Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin level less than 0.1 ng/ug (1 IEU/ug) as determined by LAL test.
PREDICTED MOLECULAR WEIGHT:25.24 kD
PHYSICAL STATE:Lyophilized
BUFFER:Lyophilized from a 0.2 um filtered solution of 20mM HEPES, 150mM NaCl, pH 7.5. It is not recommended to reconstitute to a concentration less than 100 ug/ml. Dissolve the lyophilized protein in ddH2O.
STORAGE CONDITIONS:Lyophilized protein should be stored at -20˚C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7˚C for 2-7 days.
Aliquots of reconstituted samples are stable at -20˚C for 3 months.
psi-iconAdditional Info
ALTERNATE NAMES:Azurocidin, Cationic Antimicrobial Protein CAP37, Heparin-Binding Protein, HBP, AZU1, CAP37
ACCESSION NO.:P20160
OFFICIAL SYMBOL:AZU1
GENE ID:566
psi-iconBackground and References
BACKGROUND:Azurocidin is an Azurophil granule antibiotic protein, with monocyte chemotactic and antibacterial activity. The Azurophil granules, specialized lysosomes of the neutrophil, contain at least 10 proteins implicated in the killing of microorganisms. Azurocidin is a member of the serine protease family that includes Cathepsin G, Neutrophil Elastase (NE), and Proteinase 3 (PR3), however, Azurocidin is not a serine proteinase since the active site serine and histidine residues are replaced. Human Azurocidin together with NE and PR3 are expressed coordinately and are packaged together into azurophil granules during neutrophil differentiation. Azurocidin has been identified as a modulator of endothelial permeability and an important multifunctional inflammatory mediator. Neutrophils arriving first at sites of inflammation release Azurocidin which acts in a paracrine fashion on endothelial cells causing the development of intercellular gaps and allowing leukocyte extravasation. Azurocidin thus be regarded as a reasonable therapeutic target for a variety of inflammatory disease conditions.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.